lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma
Sign Up to like & getrecommendations! Published in 2021 at "Oncology Letters"
DOI: 10.3892/ol.2021.12716
Abstract: Bone and soft-tissue sarcomas are rare and are highly heterogeneous mesenchymal malignancies. It is therefore challenging to acquire the clinical data of patients with specific histological subtypes of sarcoma using large clinical trials, and there… read more here.
Keywords: pazopanib; potential predictive; lncrna har1b; patients sarcoma ... See more keywords